Our Story

RegenArtis Private Limited is developing in vitro human skin model by 3D Bioprinting which can be used for screening new therapeutics. This approach can offer major breakthroughs in basic science and medical research. At the same time, it can significantly reduce the need for unnecessary killing of animals in laboratories.

How RegenArtis can marshal the field of drug screening procedures?

Anatomical and Immunological relevance to diseased tissue microenvironment.

  • 3D bioprinting technology will allow cellular orientation guided by various topological and biochemical cues through various cell-cell as well as cell-matrix interactions to simulate a functional tissue construct.
  • Development of in vitro disease conditions guided by immune cell infiltrations to mimic the immunological niche more accurately.

Alternative to expensive tedious animal model studies.

  • Stringent animal welfare regulations by PETA made Drugs and Cosmetic manufacturing companies to devise alternative strategies to minimize unnecessary torture and discomfort to animals.
  • Using human cells itself will allow us to gain a more realistic insight into the drug screening procedures as results from animals cannot be directly translated to humans.

Generate scalable patient-specific 3D disease models.

  • Collaborations with different hospitals and companies will allow us to predict treatment outcomes and medicines, a step forward towards personalized medicine.
  • Enhanced reproducibility using 3D Bioprinting technology will aid in scaling up of in vitro tissue models.